# Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

> **NCT01498978** · PHASE2 · COMPLETED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 10 (actual)

## Conditions studied

- Adenocarcinoma of the Prostate
- Hormone-resistant Prostate Cancer
- Recurrent Prostate Cancer
- Stage IV Prostate Cancer

## Interventions

- **BIOLOGICAL:** ipilimumab
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01498978
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-06
- **Primary completion:** 2017-02-28
- **Final completion:** 2019-01-19
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2020-10-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01498978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01498978, "Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01498978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*